Frank Lee serves as Chief Executive Officer of Pacira BioSciences, Inc., a biopharmaceutical company dedicated to advancing non-opioid pain management and regenerative health solutions. With more than 25 years of leadership experience in the pharmaceutical and medical device sectors, Lee joined Pacira in April 2020 as Chief Operating Officer before ascending to CEO in April 2021. His prior roles include President and Chief Operating Officer at Mallinckrodt Pharmaceuticals, where he directed global commercial operations, research and development, manufacturing, and medical affairs. Earlier in his career, he held progressive leadership positions at Covidien (now part of Medtronic), culminating as Group President of the Medical Supplies and Perioperative Care businesses, overseeing a portfolio exceeding $3 billion in annual revenue. Under Lee's stewardship, Pacira has achieved substantial milestones, including accelerating revenue growth for its flagship product, EXPAREL (bupivacaine liposome injectable suspension), through expanded indications, enhanced market access, and innovative commercial strategies. He has spearheaded the company's pivot toward a diversified non-opioid portfolio, including the acquisition and integration of assets like ZILRETTA and iovera°, while strengthening R&D pipelines in acute and chronic pain. His efforts have delivered consistent financial performance, with Pacira reporting record net product revenues and improved profitability amid a shifting healthcare landscape. As CEO, Frank Lee drives Pacira's mission to transform pain management by prioritizing patient outcomes, operational efficiency, and strategic partnerships. A graduate of Washington University in St. Louis with an MBA and a BS in Biology, Lee's proven track record in scaling businesses, launching blockbuster products, and navigating complex regulatory environments positions him to lead Pacira into its next phase of growth and innovation.